Xofigo

Xofigo (Radium Ra 223 Dichloride) is a radiopharmaceutical used for targeted alpha therapy in certain cancers. Administered via intravenous infusion, it helps manage symptoms in advanced prostate cancer. Suitable for patients with symptomatic bone metastases. Always consult a healthcare provider for suitability.

Xofigo is primarily used to treat adults with castration-resistant prostate cancer that has spread to the bones. It targets cancer cells in the bones with alpha particles, helping to reduce pain and slow disease progression. This therapy is often considered when other treatments are no longer effective. It is not a cure but aims to improve quality of life.

Patients receiving Xofigo may experience a reduction in bone pain and fewer complications from bone metastases. The treatment works by emitting alpha radiation that targets cancerous bone areas while minimizing damage to healthy tissue. Some may notice improved mobility or reduced need for pain medication over time.

Xofigo should only be handled and administered by trained healthcare professionals in a controlled setting. Patients may need to avoid close contact with others for a short period after treatment due to radiation exposure. Hydration and regular monitoring are typically recommended during therapy.

No significant drug interactions have been established with Xofigo, but caution is advised when combining with other systemic cancer therapies. Radiation exposure from Xofigo may accumulate with other radiopharmaceuticals or external beam radiation. Always inform your doctor about all medications and treatments being used.